Single PEMF Session Cuts Chronic Pain and Boosts Vagal Tone Simultaneously

Chronic musculoskeletal pain (CMP) affects a large portion of the adult population and is increasingly understood as a systemic condition involving not just peripheral tissue damage but also central sensitization and autonomic nervous system (ANS) dysregulation. Individuals with CMP consistently show reduced heart rate variability (HRV), reflecting parasympathetic withdrawal and sympathetic dominance. Despite this known link between pain and autonomic function, few studies have tested whether a single non-invasive intervention can simultaneously improve both domains. This pilot study set out to fill that gap using the PAPIMI device, a high-intensity pulsed electromagnetic field (PEMF) system.

Thirty adults (20 female, 10 male; mean age 49.5 ± 12.9 years) with CMP of more than three months' duration — primarily low back pain, cervicobrachialgia, and shoulder bursitis — were enrolled at a physiotherapy clinic in Lucca, Italy. All participants were treatment-naive to PAPIMI. Each received a single 30-minute session with the PAPIMI ASKLIPIOS device, which delivers ultra-short electromagnetic pulses at approximately 2.5 Hz, with magnetic induction intensity of 50–150 mT near the coil. The circular coil applicator (18 cm diameter) was positioned roughly 4 cm from the skin over the painful area. Participants abstained from caffeine, alcohol, and vigorous exercise for 24 hours prior.

Subjective pain was measured using the 11-point Numeric Pain Rating Scale (NPRS) immediately before and after the session. Autonomic function was assessed via 5-minute resting HRV recordings using a Polar H7 chest strap, with offline analysis in Kubios HRV Premium 3.4.1. Time-domain metrics included RMSSD, NN50, pNN50, and SDNN; frequency-domain metrics included LF power, HF power, and LF/HF ratio. Pre-to-post changes were analyzed with the Wilcoxon Signed-Rank test, and Spearman correlations were computed between pain score changes and HRV parameter changes.

Results were clear and statistically robust. NPRS scores fell significantly after the single PAPIMI session (p < 0.001), indicating meaningful acute pain relief. Among HRV parameters, RMSSD increased significantly (p = 0.015) and HF power — a direct index of parasympathetic/vagal activity — also rose significantly (p = 0.029). Other HRV metrics including SDNN, NN50, pNN50, LF power, and LF/HF ratio did not reach statistical significance, suggesting the effect was specifically parasympathetic rather than a broad autonomic shift. Crucially, Spearman correlations between post-intervention changes in NPRS and all HRV parameters were non-significant, indicating that pain relief and autonomic improvement occurred independently rather than as coupled responses.

The authors propose several mechanistic explanations: PEMF-induced restoration of cellular membrane potentials, enhanced microcirculation, and direct modulation of nociceptive pathways may account for pain relief, while the parasympathetic HRV shift may reflect a separate electromagnetic effect on vagal nuclei or brainstem circuits. The independence of these two effects is scientifically interesting — it suggests PAPIMI may engage multiple physiological targets simultaneously rather than one driving the other. For clinicians managing CMP, this raises the possibility of using PAPIMI as a rapid adjunct that addresses both patient-reported pain and measurable autonomic dysregulation in a single session. Limitations include the absence of a sham control group, small sample size, single-session design, and lack of long-term follow-up, all of which preclude causal conclusions and generalizability.